{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:22:34Z","timestamp":1748676154218},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the effect of topical nonsteroidal anti-inflammatory drugs (NSAIDs,) bromfenac on the intraretinal cystic lesions (IRC) when performing simultaneous cataract and idiopathic epiretinal membrane (iERM) surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included patients with iERM who had been followed up for 6 months after vitrectomy, membrane removal, and concurrent cataract surgery. Eyes were treated with topical bromfenac or not. The baseline fluorescein angiography (FA) was obtained to assess the microvascular leakage (ML). Structural changes of macula, including IRC and central macular thickness (CMT) were assessed using optical coherence tomography (OCT). The main outcome measures were changes in IRCs and best-corrected visual acuity (BCVA) regarding FA findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred eighteen eyes were included. IRC and ML were observed in 51 eyes (43.2%) and 63 eyes (53.4%), respectively. The IRC did not show any association with the ML. Of total, 29 eyes (24.6%) were treated with topical bromfenac (Group A). Compared to Group B, topical bromfenac did not show beneficial effects in aspect of preventions for the newly developed IRC and treatment for pre-existed IRC. Whether the ML existed or not, topical bromfenac did not show any different effect on the changes in BCVA and IRC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>When performing simultaneous cataract and ERM surgery, topical NSAIDs, bromfenac did not show beneficial effects on the preventions and treatment of IRC in both eyes with and without the ML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-024-03380-2","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:01:37Z","timestamp":1710511297000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of topical bromfenac on intraretinal cystoid lesion in simultaneous cataract and idiopathic epiretinal membrane surgery"],"prefix":"10.1186","volume":"24","author":[{"given":"EunAh","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Jo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Who","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iksoo","family":"Byon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"6","key":"3380_CR1","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.5301\/EJO.2010.6050","volume":"21Suppl","author":"S Scholl","year":"2011","unstructured":"Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21Suppl(6):S10\u201319.","journal-title":"Eur J Ophthalmol"},{"key":"3380_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ajo.2012.07.013","volume":"155","author":"G Mylonas","year":"2013","unstructured":"Mylonas G, Sacu S, De\u00e1k G, Dunavoelgyi R, Buehl W, Georgopoulos M, et al. Macular edema following cataract surgery in eyes with previous 23-gauge vitrectomy and peeling of the internal limiting membrane. Am J Ophthalmol. 2013;155:253\u201359.","journal-title":"Am J Ophthalmol"},{"key":"3380_CR3","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1097\/IAE.0000000000003223","volume":"41","author":"HJ Kwon","year":"2021","unstructured":"Kwon HJ, Park SW, Lee JE, Byon I, Microvascular leakage is a poor. prognostic factor for idiopathic epiretinal membrane: a Fluorescein Angiography Study. Retina. 2021;41:2515\u201322.","journal-title":"Retina"},{"key":"3380_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/IAE.0000000000003087","volume":"41","author":"DH Lee","year":"2021","unstructured":"Lee DH, Park SE, Lee CS, Microcystic macular edema, and cystoid macular edema before and after epiretinal membrane surgery. Retina. 2021;41:1652\u201359.","journal-title":"Retina"},{"key":"3380_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12886-019-1289-5","volume":"20","author":"JJ Lee","year":"2020","unstructured":"Lee JJ, Jo YJ, Kwon HJ, Lee SM, Park SW, Byon I, et al. Perioperative intraretinal fluid observed using optical coherence tomography in the epiretinal membrane. BMC Ophthalmol. 2020;20:33.","journal-title":"BMC Ophthalmol"},{"key":"3380_CR6","doi-asserted-by":"crossref","unstructured":"Quintana NE, Allocco AR, Ponce JA, Magurno MG. Nonsteroidal anti-inflammatory drugs in the prevention of cystoid macular edema after uneventful cataract surgery. Clin Ophthalmol. 2014:8:1209\u201312.","DOI":"10.2147\/OPTH.S61604"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0886-3350(03)00233-5","volume":"29","author":"DS Rho","year":"2003","unstructured":"Rho DS. Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus Ketorolac. J Cataract Refract Surg. 2003;29:2378\u201384.","journal-title":"J Cataract Refract Surg"},{"key":"3380_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.2147\/OPTH.S86971","volume":"10","author":"JD Sheppard","year":"2016","unstructured":"Sheppard JD. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clin Ophthalmol. 2016;10:2099\u2013111.","journal-title":"Clin Ophthalmol"},{"key":"3380_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/IAE.0b013e3181b094e6","volume":"29","author":"JS Heier","year":"2009","unstructured":"Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stolleret GL, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009;29:1310\u201313.","journal-title":"Retina"},{"key":"3380_CR10","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1097\/IAE.0000000000002674","volume":"40","author":"MR Pastore","year":"2020","unstructured":"Pastore MR, De Giacinto C, Cirigliano G, D\u2019Aloisio R, Addobbati R, Agostinis C, et al. Vitreous prostaglandin e2 changes after topical dministration of diclofenac 0.1%, indomethacin 0.5%, nepafenac 0.3%, and bromfenac 0.09. Retina. 2020;40:1838\u201345.","journal-title":"Retina"},{"key":"3380_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2013.5692","volume":"132","author":"SD Schoenberger","year":"2014","unstructured":"Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol. 2014;132:150\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"3380_CR12","doi-asserted-by":"publisher","first-page":"e14821","DOI":"10.1016\/j.ophtha.2011.01.034","volume":"118","author":"SD Schoenberger","year":"2011","unstructured":"Schoenberger SD, Miller DM, Petersen MR, Foster RE, Riemann CD, Sisket RA, et al. Nepafenac for epiretinal membrane surgery. Ophthalmology. 2011;118:e14821\u20133.","journal-title":"Ophthalmology"},{"key":"3380_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/14656566.7.1.99","volume":"7","author":"HD Perry","year":"2006","unstructured":"Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother. 2006;7:99\u2013107.","journal-title":"Expert Opin Pharmacother"},{"key":"3380_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2016.12.006","volume":"175","author":"A Govetto","year":"2017","unstructured":"Govetto A, Lalane RA, Sarraf D, Figueroa MS. Jean Pierre Hubschman. Insights into Epiretinal membranes: Presence of Ectopic Inner Foveal Layers and a New Optical Coherence Tomography Staging Scheme. Am J Ophthalmol. 2017;175:99\u2013113.","journal-title":"Am J Ophthalmol"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","volume":"10","author":"M Ahuja","year":"2008","unstructured":"Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008;10:229\u201341.","journal-title":"AAPS J"},{"key":"3380_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02713680490513164","volume":"29","author":"T Oka","year":"2004","unstructured":"Oka T, Shearer T, Azuma M. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res. 2004;29:27\u201334.","journal-title":"Curr Eye Res"},{"key":"3380_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1476-5381.1989.tb12676.x","volume":"98","author":"M Goppelt-Struebe","year":"1989","unstructured":"Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase\/PGE isomerase. Br J Pharmacol. 1989;98:1287\u201395.","journal-title":"Br J Pharmacol"},{"key":"3380_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/IAE.0000000000000860","volume":"36","author":"A Russo","year":"2016","unstructured":"Russo A, Morescalchi F, Vezzoli S, Bernini M, Turano R, Costagliola C, Reduction of vitreous prostaglandin e2 levels after topical administration of indomethacin, et al. 0.5%, bromfenac 0.09%, and nepafenac 0.1. Retina. 2016;36:1227\u201331.","journal-title":"Retina"},{"key":"3380_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0002-9394(14)76851-5","volume":"112","author":"AJ Flach","year":"1991","unstructured":"Flach AJ, Jampol LM, Weinberg D, Kraff MC, Yannuzzi LA, Campo RV, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991;112:514\u201319.","journal-title":"Am J Ophthalmol"},{"key":"3380_CR20","doi-asserted-by":"crossref","unstructured":"Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034-38;discussion 2039.","DOI":"10.1016\/S0161-6420(00)00365-1"},{"key":"3380_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0021-5155(99)00176-8","volume":"44","author":"K Miyake","year":"2000","unstructured":"Miyake K, Masuda K, Shirato S, Eguchi K, Hoshi H, Majima Y, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol. 2000;44:58\u201367.","journal-title":"Jpn J Ophthalmol"},{"key":"3380_CR22","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1111\/aos.14873","volume":"100","author":"ED Mandelcorn","year":"2022","unstructured":"Mandelcorn ED, Al-Falah M, Zhao LD, Kertes P, Devenyi R, Lam W. A prospective randomized clinical trial comparing nepafenac, intravitreal triamcinolone and no adjuvant therapy for epiretinal membrane. Acta Ophthalmol. 2022;100:e297\u2013303.","journal-title":"Acta Ophthalmol"},{"key":"3380_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/IAE.0000000000003819","volume":"43","author":"HJ Kwon","year":"2023","unstructured":"Kwon HJ, Kang MS, Park SW, Byon I. Topographic Assessment of Intraretinal Cystoid Space and its prognostic values in idiopathic Epiretinal membrane. Retina. 2023;43:1321\u201330.","journal-title":"Retina"},{"key":"3380_CR24","doi-asserted-by":"publisher","first-page":"10608","DOI":"10.1038\/s41598-017-08997-6","volume":"7","author":"BP Applewhite","year":"2017","unstructured":"Applewhite BP, Babapoor-Farrokhran S, Poon D, Hassan SJ, Wellmann E, Ying HS, et al. Lack of evidence for Vasoactive and Inflammatory mediators in the Promotion of Macular Edema Associated with Epiretinal membranes. Sci Rep. 2017;7:10608.","journal-title":"Sci Rep"},{"key":"3380_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/IAE.0b013e318229b1f7","volume":"32","author":"JH Ahn","year":"2012","unstructured":"Ahn JH, Park HJ, Lee JE, Oum BS. Effect of intravitreal triamcinolone injection during vitrectomy for idiopathic epiretinal membrane. Retina. 2012;32:892\u20136.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03380-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:03:11Z","timestamp":1710511391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03380-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03380-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project conformed to the tenets of the Declaration of Helsinki and obtained ethical approval from the the Institutional Review Board of the Pusan National University Hospital (approval no. 2209-014-119). Each patient was informed of the risks and benefits of the examinations and surgical treatment, and written informed consent was obtained from all patients. The study adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}